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Background
In polyposis, the type and numbers of polyps, the pat-
tern of inheritance, and any extraintestinal features are
all important in strategic planning of the DNA muta-
tional approach. But where should we go when no
mutation is uncovered? This paper outlines an approach
we have adopted at RMH.
Multiple adenomatous polyposis
As a routine, we check to see if both sequencing and
MLPA has been complete for APC, and full sequencing
for MYH (though the return outside the three common
mutations is low in our ethnic mix). On at least one
occasion, a change in the MLPA kit by Holland Inc lead
to identification of an important deletion as the probes
changed in the MLPA kit. So recollecting blood to run
on a new kit can be informative. RNA studies may also
identify expression perturbations leading to closer scru-
tiny of the DNA. We then look for translocations by
FISH analysis. If all this is negative, we move the patient
to a research setting; Justine Marum is well into a PhD
evaluating the role of AXIN mutations in this group of
patients. The findings to date are being confirmed with
other approaches to establishing pathogenicity of the
AXIN variants identified. This work is being done also
in collaboration with Dr Marie Faux at the Ludwig Insti-
tute of Cancer Research and Prof Rodney Scott at Uni-
versity of Newcastle.
Clinically, patients with multiple adenomas even with-
out a germline mutation identified, are at increased risk
of colorectal cancer; indeed, multiplicity of adenomas is
the highest risk factor of subsequent colorectal cancer
identifiable. The new NHMRC guidelines out for public
comment recommend follow up of patients: As multipli-
city of adenomas is a strong determinant of risk of meta-
chronous advanced and non advanced neoplasia, follow
up should be at twelve months for those with five or
more adenomas, and sooner in those with ten or more
adenomas.
The risk of colorectal cancer to relatives of patients
with multiple adenomas is related to the number of ade-
nomas in the proband – outside FAP and MYH. There-
fore, as distinct from patients with small numbers of
adenomas, relatives of patients with larger numbers (10
+) should be offered colonoscopy at an age relative to
the age of presentation of the proband. The interval is
not well defined but I would suggest 5 yearly.
Hyperplastic polyposis
HPS has no defined genetic basis as yet. These patients
are at high risk of colorectal cancer, either through the
serrated pathway or through their concurrent adenomas.
Two yearly colonoscopy is advised. Although the mode
of inheritance is also poorly defined, it is thought it may
be recessive. Therefore siblings are offered surveillance,
though usually not expected to be found with HPS
themselves. There is however, a high risk of colorectal
cancer in first degree relatives (siblings or parents) so
colonoscopy should be offered to these relatives 5 yearly.
Low level mosaicism, gonadal mosaicism, somatic
mosaicism
Somatic mosaicism is now well described in FAP, with
respect to the APC gene; cases of multiple adenomatous
polyposis may therefore be found with no germline
(lymphocytic) APC mutation. We have been searching
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background mucosa, in these patients without definitive
progress, but others have reported this phenomenon.
Some of this can be traced to low level mosaicism
including even in the germline (lymphocytes) but not
detected with standard approaches to APC mutational
analysis. We have also been interested to seek evidence
of gonadal mosaicism in the parents of apparent de
novo cases, and are still pursuing this possibility. This
requires predictive DNA testing of all siblings of appar-
ent de novo cases, and their parents. Gonadal mosaicism
in FAP has been reported in Utah. Recently we have
had occasion to consider whether mosaicism may
involve both the gonads and the colon – through a
request to colonoscope parents who tested negative for
an apparent de novo APC mutation in their only child.
This has lead to a range of opinions and experiences
described from colleagues around the world which will
be of interest to the FCC counsellors.
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